As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
HOME > ORGANIZATION
ORGANIZATION
- Shipments Restricted or Suspended for 22.4% of Products in July, No Sign of Improvement: FPMAJ
August 31, 2023
- JPMA on Alert for IRA’s Drug Pricing Provisions, Boosting Cooperation with PhRMA
August 29, 2023
- As 2040 Doctor Shortage Looms, Japan Consumer Healthcare Group Pushes Rx-to-OTC Switches for Hypertension Meds
August 25, 2023
- Japan Citizens’ Group Objects to HPV Vaccination in Males
August 25, 2023
- JPMA Taskforce Issues Proposal on Information Supply, Drug Development for Rare Diseases
August 18, 2023
- Economic Burden of Preventable Cancer “Over 1 Trillion Yen”: NCC, NCGM
August 17, 2023
- INES Proposes Extension of Public Funding for COVID Drugs
August 7, 2023
- IRA Could Create New Type of Drug Loss, Affecting Japan Too: PhRMA Official
July 31, 2023
- Shipments of 22.3% of Products Restricted or Suspended in June: FPMAJ
July 24, 2023
- JPA to Issue Policy Proposal to Address Lingering Supply Crisis
July 24, 2023
- More People Seek Self-Medication Tax Break in 2022
July 24, 2023
- JPMA Says IRA Is “Alarming,” Set to Exchange Views with PhRMA
July 21, 2023
- Pseudonymised Data Should Fuel Orphan Drug Discovery, but Criteria and Overseas Usage Must Be Discussed: JPMA
July 21, 2023
- Policy Veterans’ Group Lauds Expert Panel’s Report as “Epoch Making”
July 20, 2023
- Drug Reps in Japan Decline for 9th Consecutive Year, Falling Below 50,000: FY2022 Report
July 19, 2023
- Reform Regenerative Medicine Systems to Fight Lag, Loss: FIRM to Japan Govt
July 12, 2023
- Stop Requiring Japanese PI Data for Global Products: JPMA Officials
July 10, 2023
- PhRMA Urges Japan to Offer Coverage for CGP Testing in First-Line Setting
July 4, 2023
- Generic Use Rate at 80.7% in FY2022: JGA
June 30, 2023
- Citizens’ Group Opposes Pilot Switch Program for Emergency Contraceptives
June 27, 2023
ページ
A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…